Security Snapshot

SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) Institutional Ownership

CUSIP: 869367102

13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

6

Shares (Excl. Options)

290,035

Price

$11.57

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
STRO on Nasdaq
Shares outstanding
16,611,035
Price per share
$24.92
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
290,035
Total reported value
$3,355,706
% of total 13F portfolios
0%
Share change
-53,066,205
Value change
-$74,008,020
Number of holders
6
Price from insider filings
$24.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 869367102.
  • 6 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 6 to 2 between Q4 2025 and Q1 2026.
  • Reported value moved from $3,355,706 to $2,641.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 6 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
VANGUARD GROUP INC 4.9% $2,937,877 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,493,679 -$2,892,242 2,092,281 -66% BlackRock, Inc. 30 Jun 2025
Point72 Asset Management, L.P. 5.7% $23,590,623 946,829 Point72 Asset Management, L.P. 24 Apr 2026
PERCEPTIVE ADVISORS LLC 5.4% $22,370,431 898,025 Perceptive Advisors LLC 14 Apr 2026
MILLENNIUM MANAGEMENT LLC 1.3% -72% $5,240,663 -$112,268,464 210,378 -96% Millennium Management LLC 31 Mar 2026

As of 31 Dec 2025, 6 institutional investors reported holding 290,035 shares of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO). This represents 1.7% of the company’s total 16,611,035 outstanding shares.

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 106 $2,641 $24.92 2
2025 Q4 290,035 $3,355,706 -$74,008,020 $11.57 6
2025 Q3 53,354,083 $46,329,126 -$1,641,183 $0.87 84
2025 Q2 55,585,121 $39,680,994 -$3,651,726 $0.71 100
2025 Q1 61,457,334 $39,985,859 -$10,841,219 $0.65 113
2024 Q4 63,895,959 $117,565,386 -$7,306,459 $1.84 122
2024 Q3 62,516,525 $216,373,636 -$1,660,759 $3.46 130
2024 Q2 63,167,394 $185,075,042 +$25,139,079 $2.93 119
2024 Q1 53,412,221 $301,719,025 +$2,094,339 $5.65 116
2023 Q4 55,648,249 $238,729,642 -$219,480 $4.29 113
2023 Q3 55,996,442 $194,308,615 +$5,622,550 $3.47 108
2023 Q2 54,105,078 $251,585,717 +$2,181,872 $4.65 119
2023 Q1 53,720,779 $247,499,715 +$10,470,599 $4.62 114
2022 Q4 49,984,035 $403,859,817 +$6,296,600 $8.08 116
2022 Q3 50,396,383 $279,697,401 +$23,514,794 $5.55 111
2022 Q2 46,245,672 $240,931,373 +$15,713,924 $5.21 111
2022 Q1 41,606,389 $341,990,813 -$38,514,469 $8.22 111
2021 Q4 39,677,298 $590,411,817 -$4,363,219 $14.88 114
2021 Q3 39,817,120 $752,214,523 -$26,368,206 $18.89 119
2021 Q2 41,241,047 $766,657,023 -$71,886,996 $18.59 121
2021 Q1 44,209,991 $1,005,487,689 +$114,863,310 $22.76 136
2020 Q4 39,392,744 $855,224,796 +$184,675,658 $21.71 132
2020 Q3 31,151,440 $313,088,624 +$67,545,691 $10.05 87
2020 Q2 23,997,579 $186,238,799 +$97,614,730 $7.76 76
2020 Q1 11,868,607 $116,270,683 +$7,872,102 $10.20 60
2019 Q4 11,616,437 $127,772,633 +$7,088,075 $11.00 64
2019 Q3 11,074,608 $91,621,057 -$8,301,817 $9.09 59
2019 Q2 11,817,484 $122,739,770 +$6,666,665 $11.38 58
2019 Q1 11,231,778 $116,185,606 +$4,727,906 $11.39 49
2018 Q4 9,707,399 $87,234,000 -$10,616,486 $9.02 41
2018 Q3 9,086,875 $135,767,000 +$129,306,000 $15.00 32
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .